<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Giovanna Brunasso, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cesare Massone, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H77149456"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Palmoplantar pustulosis (PPP) is a chronic inflammatory condition characterized by crops of sterile pustules on the palms and soles that erupt repeatedly over time  (<a class="graphic graphic_picture graphicRef75404 graphicRef62582 graphicRef82843 graphicRef93903 graphicRef93904 graphicRef93905" href="/z/d/graphic/75404.html" rel="external">picture 1A-F</a>). Yellow-brown macules (remnants of resolving pustules), erythema, scale, and fissures are additional frequent findings. Other terms that have been used to refer to PPP are palmoplantar pustular psoriasis, pustulosis palmoplantaris, and pustulosis palmaris et plantaris.</p><p>Despite the limited area of skin involvement in PPP, the condition can have a significant negative effect on quality of life. Symptoms of pruritus, burning sensations, or pain are often present. In severe cases, the discomfort associated with skin involvement can cause difficulty with walking or other activities of daily living.</p><p>The clinical features and diagnosis of PPP will be reviewed here. Other pustular disorders, including acrodermatitis continua of Hallopeau (an acral variant of pustular psoriasis that primarily involves the digits) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/93852.html" rel="external">"Palmoplantar pustulosis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/1733.html" rel="external">"Approach to the patient with pustular skin lesions"</a> and  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Acrodermatitis continua of Hallopeau'</a> and  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H1352551"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The classification of palmoplantar pustulosis (PPP) is controversial. While some authors propose that PPP is a variant of psoriasis [<a href="#rid1">1,2</a>], others consider the disease a separate condition [<a href="#rid3">3-10</a>].</p><p>A consensus statement from the European Rare and Severe Psoriasis Expert Network (ERASPEN) recognizes psoriasis vulgaris and pustular psoriasis as distinct phenotypes and classifies PPP as a variant of pustular psoriasis [<a href="#rid11">11</a>]. In the ERASPEN classification scheme, PPP is subclassified as occurring "with or without psoriasis."</p><p>Authors who consider PPP a subtype of psoriasis have done so based upon the recognition of similarities between the conditions. As an example, our retrospective study comparing 39 patients with PPP and 51 patients with palmoplantar plaque psoriasis (a nonpustular form of psoriasis characterized by erythematous scaly plaques on the palms and soles) did not find statistically significant differences in age of onset, disease duration, family history of psoriasis, concomitant arthritis, or smoking habits between the two groups [<a href="#rid1">1</a>]. In addition, erythematous, scaly plaques similar to those of palmoplantar plaque psoriasis frequently accompanied pustules in PPP.</p><p>Other findings that suggest a direct relationship between PPP and psoriasis include the detection of psoriasis-like plaques on the trunk or extremities of some patients with PPP [<a href="#rid12">12</a>]. Moreover, a family history of psoriasis has been reported in 10 to 43 percent of patients with PPP [<a href="#rid1">1,7</a>]. A Scottish retrospective study of 73 patients with PPP found a family history of chronic plaque psoriasis or PPP in 21 and 3 percent of patients, respectively, a concomitant diagnosis of PPP and chronic plaque psoriasis in 27 percent, and concurrent psoriatic arthritis in 12 percent. These prevalences are 10 to 15 times higher than in the general population and suggest a close association between the two diseases [<a href="#rid7">7</a>].</p><p>Observations used to negate the designation of PPP as a variant of psoriasis include the strong association of PPP with smoking (an association much stronger than psoriasis vulgaris), the female predominance in PPP, the lack of an association between PPP and the psoriasis susceptibility locus PSORS1 (the major genetic determinant for psoriasis vulgaris) [<a href="#rid13">13</a>], the association of PPP with metal allergies [<a href="#rid8">8,9,14</a>], and differences in the response of PPP and psoriasis to therapy. Further study of the pathogenic mechanisms of PPP may help to resolve the controversy over the relationship between psoriasis and PPP. (See <a class="local">'Pathogenesis'</a> below.)</p><p class="headingAnchor" id="H77149462"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Epidemiologic data on palmoplantar pustulosis (PPP) are limited. In general, PPP appears to be uncommon in the general population. A review of studies assessing the prevalence of PPP from Sweden, Korea, Germany, and Japan found prevalence rates of 0.05 to 0.12 percent [<a href="#rid15">15</a>]. In our personal experience in an academic dermatology practice, PPP seems to present slightly more often.</p><p>PPP usually develops in middle-aged adults. The mean age of onset in a retrospective study that included 39 patients with PPP was 48 years [<a href="#rid1">1</a>]. In the nationwide Japanese study, the highest prevalences for PPP occurred between the ages of 50 and 69 years [<a href="#rid6">6</a>]. PPP occurs more frequently in women than in men; observational studies from various parts of the world have found proportions of female patients ranging from 58 to 94 percent [<a href="#rid1">1,6-10,16,17</a>].</p><p class="headingAnchor" id="H77149468"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of palmoplantar pustulosis (PPP) is not fully understood. Contributions of components of both the innate and adaptive immune systems are proposed. Environmental exposures and genetic susceptibility also may contribute to PPP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism </strong>– Studies investigating the mechanisms of PPP have yielded several observations regarding the development of this disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The acrosyringium appears to be the primary site of vesicle/pustule formation and inflammation [<a href="#rid18">18</a>], and an abnormality in sweating may contribute to the formation of vesicles and pustules in PPP [<a href="#rid19">19</a>]. The finding that patients with PPP in Japan increase use of health care services during the hot season compared with the cold season may also support a role for sweating as a contributor to PPP [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The inflammatory process that destroys the acrosyringium involves lymphocytes, neutrophils, eosinophils, and mast cells [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased numbers of Langerhans cells have been detected around sweat ducts in PPP skin, suggesting the possibility of an antigen-driven process [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Specific chemotactic factors may contribute to the development or propagation of the inflammatory process in PPP:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased expression of interleukin (IL) 8 (a known neutrophil chemoattractant) and IL-17 related cytokines (eg, IL-17A, IL-17C, IL-17 D, IL-17 F, IL-22, IL-23A, IL-23 receptor) has been detected in PPP tissue [<a href="#rid21">21,22</a>]; in particular, expression of IL-17 has been detected within the acrosyringium [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased serum levels of tumor necrosis factor-alpha (TNF-alpha), IL-17, IL-22, and interferon-gamma (IFN-gamma) have been detected in patients with PPP [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A hyperimmune response to group A streptococci in tonsillar mononuclear cells has been described in PPP, and a tonsil-induced, autoimmune/inflammatory response might play a pathogenic role in PPP pathogenesis. In particular, cutaneous lymphocyte antigen (CLA), chemokine receptor CCR6, and integrin beta-1 may play an important role in the recruitment of T cells from the tonsils to the skin lesions of PPP [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complement pathway activation has been demonstrated inside PPP vesicles containing neutrophil-chemotactic C5a anaphylatoxin; the stratum corneum activates the alternative complement pathway, resulting in neutrophilic chemotaxis [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The antimicrobial peptide LL-37 may contribute to neutrophil recruitment by upregulating IL-8 (neutrophil activation), IL-23, IL-17C, IL-1-alpha, and IL-1-beta [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Additional studies are necessary to elucidate how these factors interact in the development of PPP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental factors </strong>– Clinical observations suggest that smoking, stress, infection, and drugs may contribute to the development or exacerbation of PPP:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Smoking </strong>– There is a strong association between smoking and PPP, suggesting that smoking has a role in the pathogenesis of this disease. The reported prevalences of current or previous smoking among patients with PPP range from 38 to 100 percent [<a href="#rid1">1,7,16,17</a>]. The mechanism through which smoking could contribute to PPP has not been established. Proposed mechanisms have included effects of nicotine on sweat gland function or keratinocyte function (eg, nicotine-induced increase in keratinocyte cornification) [<a href="#rid26">26</a>]. In addition, differences in nicotine acetylcholine receptor staining patterns in PPP skin observed in a study of biopsy specimens taken from patients with PPP, healthy smokers, and healthy nonsmokers prompted consideration that an abnormal response to nicotine could contribute to inflammation [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stress </strong>–<strong> </strong>The observation that patients with PPP frequently report worsening of symptoms with stress led to a study investigating skin nerve fibers in involved skin [<a href="#rid27">27</a>]. The study found increased numbers of contacts between nerves and mast cells and intense substance P-like immunoreactivity in neutrophils in pustules and the papillary dermis, suggesting a role for neuro-mediation in the inflammatory process of PPP. In addition, a study of 21 patients with PPP and 21 age- and sex-matched controls found a higher rate of moderate to high anxiety among the patients with PPP than in the control population (61 versus 19 percent) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection </strong>– Focal infections (eg, acute or chronic tonsillitis, dental infection, chronic sinusitis) may be associated with PPP. Reports from Japan document episodes of PPP that follow infection, worsen in the setting of infection, or improve following treatment of infection [<a href="#rid29">29-31</a>]. One retrospective analysis of outcomes of PPP following dental infection control, tonsillectomy, and dental metal removal found improvement of PPP in 44 of 70 patients (63 percent) after dental infection control, 6 of 6 patients (100 percent) after tonsillectomy, and 3 of 9 patients (33 percent) after dental metal removal [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2">Also, differences in immune responses in tonsillar tissue and differences in oral microbiota that may be related to smoking or other factors have been detected in Japanese patients with PPP [<a href="#rid33">33-40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs </strong>–<strong> </strong>There are multiple reports of the development of PPP following treatment with biologic TNF-alpha inhibitors [<a href="#rid41">41-44</a>]. The mechanism behind this occurrence is not definitively known. Paradoxically, biologic TNF-alpha inhibitors have also been used for the treatment of PPP. (See  <a class="medical medical_review" href="/z/d/html/93852.html" rel="external">"Palmoplantar pustulosis: Treatment", section on 'Severe recalcitrant disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metal allergy </strong>– A role for metal allergy in the development of PPP has been suggested by some authors based upon observations in small numbers of patients [<a href="#rid7">7-9,14,45,46</a>]. One report describes an exacerbation of PPP following a strongly positive nickel patch test [<a href="#rid9">9</a>]. However, sufficient data to confirm an association are lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics </strong>– Although PPP does not appear to be associated with the PSORS1 locus that is strongly associated with psoriasis vulgaris [<a href="#rid10">10,13</a>], other genetic factors common to both diseases may influence an individual’s risk for the development of PPP. The findings of a study of 43 patients with PPP and 149 healthy controls suggest that variations of IL19, IL20, and IL24 genes may influence risk for both PPP and psoriasis vulgaris [<a href="#rid47">47</a>]. In addition, missense variants in the <em>CARD14</em> gene may be involved in the pathogenesis of PPP as well as psoriasis vulgaris and generalized pustular psoriasis [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">Other mutations that may play a role include mutations in <em>AP1S3</em> and <em>ATG16L1</em>, genes also associated with psoriasis. In psoriasis, the<em> ATG16L1</em> mutation affects the production of antimicrobial peptides and the production of IL-18 and IL-1, propagating systemic inflammation [<a href="#rid16">16,48-50</a>]. Single nucleotide polymorphisms (SNPs) of the <em>ATG16L1</em> gene have been detected in patients with PPP, supporting a genetic link between PPP and psoriasis [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">The genetic findings of patients affected by PPP with and without concomitant plaque psoriasis have been compared. A study that used gene expression microarray to compare skin biopsies from PPP with concomitant plaque psoriasis with skin biopsies from PPP without concomitant plaque psoriasis found that these entities could not be distinguished based upon gene expression, suggesting a relationship between these conditions [<a href="#rid51">51</a>]. The same authors found an increase in IL-17 gene expression without an increase in IL-23 in PPP with and without concomitant plaque psoriasis, a feature that may contribute to poor responses of PPP to <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, an inhibitor of IL-12 and IL-23 [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/93852.html" rel="external">"Palmoplantar pustulosis: Treatment", section on 'Severe recalcitrant disease'</a>.)</p><p></p><p class="headingAnchor" id="H77149480"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of palmoplantar pustulosis (PPP) consist of the classic findings on the palms or soles and associated cutaneous and extracutaneous clinical features.</p><p class="headingAnchor" id="H92958795"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>PPP is characterized by the development of recurrent crops of discrete 1 to 10 mm sterile pustules limited to the palms and/or soles  (<a class="graphic graphic_picture graphicRef75404 graphicRef62582 graphicRef82843 graphicRef93903 graphicRef93904 graphicRef93905" href="/z/d/graphic/75404.html" rel="external">picture 1A-F</a>) [<a href="#rid1">1-3,53-55</a>]. The pustules often coalesce and resolve after several days, leaving brown macules and hyperkeratosis. Well-demarcated erythema, hyperkeratosis, and desquamation often surround the sites of pustulation.</p><p>Patients with PPP may have involvement of only the palms or only the soles of the feet; however, involvement of both the palms and soles is most common [<a href="#rid1">1,26</a>]. On the hands, the thenar and hypothenar eminences and central palm are common sites for pustule development [<a href="#rid53">53,56</a>]. The instep, the medial and lateral borders of the foot across from the instep, and the sides or back of the heel are common sites of PPP on the feet. Diffuse involvement of the palms or soles can also occur  (<a class="graphic graphic_picture graphicRef94792 graphicRef94793 graphicRef82843" href="/z/d/graphic/94792.html" rel="external">picture 1C, 1G-H</a>). The distribution is usually bilateral, but may also be unilateral, particularly at the onset of disease [<a href="#rid53">53</a>].</p><p>The impact of PPP on quality of life can be significant and should not be underestimated [<a href="#rid57">57</a>]. Patients frequently experience symptoms of itching and burning in the areas of involvement, and fissures may form, resulting in pain and bleeding. Severe eruptions can inhibit the patient’s ability to walk or perform other activities that require use of the hands or feet.</p><p class="headingAnchor" id="H20900583"><span class="h2">Associated clinical findings</span><span class="headingEndMark"> — </span>Patients with PPP may develop additional clinical findings, including nonpustular cutaneous eruptions, nail dystrophy, and arthritis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extra-palmoplantar skin involvement </strong>– The development of nonpustular psoriasis-like skin eruptions in other areas, such as the forearms, elbows, dorsal feet, lower legs, knees, or buttocks, has been described in patients with PPP [<a href="#rid12">12</a>]. These extra-palmoplantar skin lesions tend to be less pronounced and less well demarcated than classic plaque psoriasis  (<a class="graphic graphic_picture graphicRef93907" href="/z/d/graphic/93907.html" rel="external">picture 2</a>). Other potential findings include scale and erythema on the scalp, and infrequently, solitary pustules in areas other than the hands and feet [<a href="#rid12">12</a>]. Extra-palmoplantar skin changes may be more likely to occur in patients with severe PPP than in patients with milder disease [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">The proportion of patients with extra-palmoplantar skin involvement is difficult to assess because some studies have intentionally excluded patients with extra-palmoplantar psoriatic lesions and reported estimates for extra-palmoplantar psoriasis in patients with PPP vary widely, ranging from 4 to 73 percent [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail abnormalities </strong>–<strong> </strong>Nail abnormalities are common in patients with PPP [<a href="#rid17">17,58,59</a>]. Subungual pustules, onycholysis, pitting, destruction of the nail, or discoloration of the nail plate may be seen  (<a class="graphic graphic_picture graphicRef93908" href="/z/d/graphic/93908.html" rel="external">picture 3</a>) [<a href="#rid58">58</a>]. In a series of 50 adults with PPP, nail abnormalities were present in 15 patients (30 percent) and subungual pustulation was the most common nail abnormality seen [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthritis </strong>– A subset of patients with PPP have concomitant arthritis, arthralgias, or unspecified forms of arthritis. In a retrospective study of 197 patients with PPP, 25 (13 percent) had documentation of arthralgias in the medical record [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">In our retrospective study of 39 patients with PPP, 10 patients also had arthritis (26 percent), in accordance to other literature reports [<a href="#rid1">1</a>]. None of these patients had SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. (See <a class="local">'SAPHO syndrome'</a> below.)</p><p></p><p class="headingAnchor" id="H6136762"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Several systemic abnormalities have been linked to palmoplantar pustulosis (PPP).</p><p class="headingAnchor" id="H2799162699"><span class="h2">Pustulotic arthro-osteitis</span><span class="headingEndMark"> — </span>Pustulotic arthro-osteitis (PAO)<strong> </strong>is a common osteoarticular comorbidity of PPP that has been estimated to occur in 20 to 30 percent of patients with PPP in Japan [<a href="#rid60">60</a>]. The condition presents with joint pain, most often involving the anterior chest wall, although other joints may also be affected. PAO primarily occurs in middle-aged females and often develops in association with focal infection [<a href="#rid60">60</a>]. Bone scintigraphy reveals increased uptake in the anterior chest wall [<a href="#rid60">60</a>]. Clinical symptoms may overlap with SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, a much less frequent disorder.</p><p class="headingAnchor" id="H1516508949"><span class="h2">SAPHO syndrome</span><span class="headingEndMark"> — </span>PPP is one of the cutaneous manifestations that may occur in patients with SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, a rare arthropathy characterized by various presentations of arthropathy and a variety of neutrophilic skin disorders [<a href="#rid61">61</a>]. The arthropathy of SAPHO syndrome commonly involves the anterior chest wall and may present with pain, tenderness, and swelling of the sternum and its articulations. (See  <a class="medical medical_review" href="/z/d/html/5622.html" rel="external">"Major causes of musculoskeletal chest pain in adults", section on 'Sternocostoclavicular hyperostosis (SAPHO syndrome)'</a>.)</p><p>Osteoarticular features often precede skin findings but may appear concomitantly or subsequent to skin involvement [<a href="#rid61">61</a>]. Other pustular skin disorders that may occur in the setting of SAPHO syndrome are psoriasis, acne conglobata, acne fulminans, dissecting cellulitis of the scalp, and hidradenitis suppurativa.</p><p class="headingAnchor" id="H2636750701"><span class="h2">Psychiatric disorders</span><span class="headingEndMark"> — </span>Psychiatric disorders may be more prevalent in patients with PPP. In a case-control study, 23 percent of 60 female patients with PPP had psychiatric comorbidity, as depression, anxiety, schizophrenia, and manic-depressive disease, compared with 5 percent of 154 healthy female controls [<a href="#rid62">62</a>]. Age-adjusted odds for psychiatric disorders were greater (odds ratio [OR] 5.6, 95% CI 2.2-14.4) for females with PPP compared with healthy controls.</p><p class="headingAnchor" id="H180950015"><span class="h2">Systemic diseases</span><span class="headingEndMark"> — </span>The relationship between PPP and systemic diseases is controversial. Limited data suggest that several systemic abnormalities may occur at increased frequency in patients with PPP, such as thyroid disease [<a href="#rid7">7,63,64</a>], disturbed calcium homeostasis [<a href="#rid62">62</a>], diabetes [<a href="#rid7">7,62</a>], and dyslipidemia [<a href="#rid1">1,7</a>]. Further studies are necessary to confirm a relationship between PPP and these conditions. Increased prevalence of gluten sensitivity was suggested by a Swedish study of 123 patients with PPP [<a href="#rid65">65</a>]; however, a German study did not find an association between PPP and gluten sensitivity, suggesting geographical or ethnic variability [<a href="#rid66">66</a>]. A case report describes a concomitant flare of PPP and new-onset sarcoidosis, which may reflect the role of tumor necrosis factor (TNF) in the pathogenesis of both disorders [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H77149523"><span class="h1">DISEASE COURSE</span><span class="headingEndMark"> — </span>Palmoplantar pustulosis often persists for several years or decades, with frequent periods of disease exacerbation and partial remissions [<a href="#rid68">68</a>]. The severity does not appear to attenuate over time, and the risk of relapses seems to remain unchanged during the patient's lifetime [<a href="#rid15">15</a>].</p><p>The disease may significantly impair quality of life secondary to discomfort and resultant functional disability.</p><p class="headingAnchor" id="H77149529"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of palmoplantar pustulosis usually can be made based upon recognition of the clinical findings of a pustular eruption limited to the palms and/or soles with associated erythema and hyperkeratosis and a clinical evaluation to rule out other conditions. Performance of a potassium hydroxide (KOH) preparation (or fungal culture) is particularly important to rule out cutaneous fungal infection as the cause of symptoms in patients with plantar involvement.</p><p>A skin biopsy is not usually necessary, but can be useful for supporting the diagnosis in patients with atypical presentations or refractory disease. A KOH preparation should be performed prior to a skin biopsy to prevent an unnecessary biopsy.</p><p class="headingAnchor" id="H180951004"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>Expected physical findings of PPP are multiple pustules on the palms and/or soles, often with surrounding erythema and hyperkeratosis. Brown macules at sites of resolving pustules, fissures, and nail changes also may be present. If vesicles rather than pustules are the primary finding, the possibility of acute palmoplantar eczema (dyshidrotic eczema) should be considered. (See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p>In addition to a physical examination of the palms and soles, a full examination of the skin and nails is indicated. The full skin examination allows the clinician to rule out generalized pustular psoriasis with palmoplantar involvement, to identify the presence of extra-palmoplantar skin lesions, and to detect additional skin manifestations that might suggest SAPHO syndrome (eg, acne, dissecting cellulitis, hidradenitis suppurativa). (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Generalized pustular psoriasis'</a> and  <a class="medical medical_review" href="/z/d/html/5622.html" rel="external">"Major causes of musculoskeletal chest pain in adults", section on 'Sternocostoclavicular hyperostosis (SAPHO syndrome)'</a>.)</p><p>The clinical evaluation should also include a review of systems that includes questions about bone or joint pain to identify symptoms suggestive of concomitant arthritis or SAPHO syndrome. Because of the potential association of PPP with thyroid abnormalities and gluten sensitivity, we also question patients about symptoms of thyroid disease or gluten sensitivity (eg, diarrhea, steatorrhea, flatulence), as well as a personal or family history of these diseases. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Gastrointestinal manifestations'</a>.)</p><p class="headingAnchor" id="H257461189"><span class="h2">Potassium hydroxide preparation</span><span class="headingEndMark"> — </span>We usually perform a potassium hydroxide (KOH) preparation in patients who present with clinical findings suggestive of PPP to rule out the possibility of a dermatophyte infection as the cause of the eruption. Alternatively, a fungal culture can be performed. (See  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p class="headingAnchor" id="H257464334"><span class="h2">Bacterial culture</span><span class="headingEndMark"> — </span>The pustules of PPP are sterile. Bacterial cultures are primarily reserved for atypical presentations to rule out infection.</p><p class="headingAnchor" id="H77149537"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Skin biopsies often are not necessary for diagnosis. However, in cases in which the diagnosis is uncertain, biopsies can be helpful for supporting the diagnosis. A 4 mm punch biopsy that includes at least a portion of a pustule and surrounding erythema is our preferred procedure. In challenging cases (eg, prior treatment or atypical clinical features), multiple biopsies may be necessary to identify the histopathologic features of PPP. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a>.)</p><p class="headingAnchor" id="H3066914"><span class="h3">Histopathology</span><span class="headingEndMark"> — </span>Histologic findings that are consistent with a diagnosis of PPP include [<a href="#rid26">26,69,70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidermal changes (parakeratosis, loss of granular layer, psoriasiform epidermal hyperplasia)</p><p class="bulletIndent1"><span class="glyph">●</span>Spongiosis or epidermal vesicle formation (in early lesions)</p><p class="bulletIndent1"><span class="glyph">●</span>Pustules filled with neutrophils and eosinophils in the upper epidermis</p><p class="bulletIndent1"><span class="glyph">●</span>Accumulation of mast cells and eosinophils below pustules in the upper dermis</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed perivascular and diffuse infiltrate in the dermis (lymphocytes, neutrophils, eosinophils, mast cells)</p><p></p><p class="headingAnchor" id="H77149555"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory tests are expected to be normal. If there is clinical suspicion for disorders that may occur at increased frequency in patients with PPP, including thyroid disease, gluten sensitivity, or diabetes, laboratory evaluation for these disorders should be initiated. (See <a class="local">'Systemic diseases'</a> above.)</p><p class="headingAnchor" id="H77149561"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several other skin disorders that may present with pustules, erythema, and/or scale on the palms or soles are included in the differential diagnosis of palmoplantar pustulosis (PPP):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar plaque psoriasis </strong>– Palmoplantar plaque psoriasis is plaque psoriasis that primarily involves the palmoplantar area. Patients present with erythematous, scaly plaques on the palms and/or soles  (<a class="graphic graphic_picture graphicRef93909" href="/z/d/graphic/93909.html" rel="external">picture 4</a>). Fissures are common. The absence of pustules distinguishes palmoplantar plaque psoriasis from PPP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute palmoplantar eczema </strong>– Acute palmoplantar eczema (dyshidrotic eczema, pompholyx) is a relapsing vesiculobullous palmoplantar disorder that most commonly presents as an acute, intensely pruritic eruption of small vesicles to large bullae on the lateral aspects of the fingers, palms, and/or soles  (<a class="graphic graphic_picture graphicRef93910 graphicRef83056 graphicRef83055" href="/z/d/graphic/93910.html" rel="external">picture 5A-C</a>). Although pustules are not a primary feature of acute palmoplantar eczema, pustules can develop as a result of secondary infection. The absence of hyperkeratotic and well-defined erythematous lesions that tend to crack in acute palmoplantar eczema facilitates the clinical distinction between PPP and acute palmoplantar eczema. The histologic findings of PPP can be difficult to distinguish from acute palmoplantar eczema with pustules because the disorders share multiple histopathologic features [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acrodermatitis continua of Hallopeau </strong>– Acrodermatitis continua of Hallopeau is a rare, chronic variant of pustular psoriasis characterized by the presence of sterile pustules involving the nails and surrounding skin of the fingers or toes  (<a class="graphic graphic_picture graphicRef93911 graphicRef69799" href="/z/d/graphic/93911.html" rel="external">picture 6A-B</a>). Associated paronychia, onychodystrophy, atrophic skin changes, and osteolysis of the distal phalanges can occur. The term acropustulosis repens has been used to describe a milder presentation [<a href="#rid71">71</a>]. The primary involvement of the digits distinguishes this disorder from PPP. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Acrodermatitis continua of Hallopeau'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vesicular/bullous tinea pedis or manuum </strong>– Vesicular tinea pedis (foot) or manuum (hand) result from dermatophyte infection of the palmar, plantar, or interdigital areas. Affected patients present with vesicles or vesicopustules with associated scale and erythema  (<a class="graphic graphic_picture graphicRef82787 graphicRef54214" href="/z/d/graphic/82787.html" rel="external">picture 7A-B</a>). A potassium hydroxide (KOH) preparation or fungal culture is useful for diagnosing this condition. (See  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea pedis'</a>.)</p><p></p><p>In rare cases, pemphigus vulgaris can present as a vesicular or vesiculopustular eruption on the palms or soles that may be confused with dyshidrotic eczema or PPP. A patient in whom pemphigus vulgaris manifesting as vesiculopustules on the palms and soles preceded other manifestations of pemphigus has been documented in a case report [<a href="#rid72">72</a>]. A biopsy revealing intraepidermal and suprabasilar acantholytic dyskeratosis and direct immunofluorescence demonstrating intraepidermal deposits of IgG confirm the diagnosis of pemphigus vulgaris. (See  <a class="medical medical_review" href="/z/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p class="headingAnchor" id="H3993496493"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/132532.html" rel="external">"Society guideline links: Palmoplantar pustulosis"</a>.)</p><p class="headingAnchor" id="H77149637"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Palmoplantar pustulosis (PPP) is a pustular skin disorder that usually occurs in adults. Women are more frequently affected than men. Many patients with PPP smoke or have a previous history of smoking. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of PPP is not well understood. Environmental factors (eg, smoking, stress, infection, and certain drugs) may contribute the disease. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – PPP usually presents as recurrent crops of pustules on the palms and/or soles  (<a class="graphic graphic_picture graphicRef75404 graphicRef62582 graphicRef82843 graphicRef93903 graphicRef93904 graphicRef93905" href="/z/d/graphic/75404.html" rel="external">picture 1A-F</a>). Brown macules representing resolving pustules, erythema, and scale are also often present. Associated symptoms of pruritus, burning sensations, or pain are common. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Extra-palmoplantar findings present in some patients with PPP include psoriasis-like skin lesions  (<a class="graphic graphic_picture graphicRef93907" href="/z/d/graphic/93907.html" rel="external">picture 2</a>), subungual pustulation and other nail abnormalities  (<a class="graphic graphic_picture graphicRef93908" href="/z/d/graphic/93908.html" rel="external">picture 3</a>), and arthritis. PPP may develop in association with SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Additional studies are necessary to clarify the relationship between PPP and thyroid disease, gluten sensitivity, and type 2 diabetes. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course</strong> – PPP exhibits a chronic clinical course characterized by exacerbations and partial remissions over the course of several years or decades. The disease can have a significant negative effect on quality of life because of the associated symptoms. (See <a class="local">'Disease course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PPP can often be made through clinical evaluation. A potassium hydroxide (KOH) preparation is useful for ruling out a superficial dermatophyte infection as the cause of the symptoms. Biopsy findings can offer support for the diagnosis when then the clinical evaluation is inconclusive. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – PPP should be distinguished from other disorders that may present with pustules, erythema, or scale on the hands or feet. Examples include palmoplantar plaque psoriasis, acute palmoplantar eczema (dyshidrotic eczema or pompholyx), acrodermatitis continua of Hallopeau, and vesicular tinea. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brunasso AM, Puntoni M, Aberer W, et al. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 2013; 168:1243.</a></li><li><a class="nounderline abstract_t">Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009; 60:1024.</a></li><li><a class="nounderline abstract_t">de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat 2011; 22:102.</a></li><li><a class="nounderline abstract_t">Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol 2008; 22:392.</a></li><li><a class="nounderline abstract_t">Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156:258.</a></li><li><a class="nounderline abstract_t">Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 2015; 5:e006450.</a></li><li><a class="nounderline abstract_t">Becher G, Jamieson L, Leman J. Palmoplantar pustulosis--a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol 2015; 29:1854.</a></li><li><a class="nounderline abstract_t">Liu F, Zhang M, Lou Y, et al. The spontaneous regression of palmoplantar pustulosis following removal of dental amalgams: A report of two cases. Australas J Dermatol 2016; 57:e93.</a></li><li><a class="nounderline abstract_t">Ito T, Mori T, Fujiyama T, Tokura Y. Dramatic exacerbation of palmoplantar pustulosis following strongly positive nickel patch testing. Int J Dermatol 2014; 53:e327.</a></li><li><a class="nounderline abstract_t">Mössner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients. J Invest Dermatol 2015; 135:2538.</a></li><li><a class="nounderline abstract_t">Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017; 31:1792.</a></li><li><a class="nounderline abstract_t">Yamamoto T. Extra-palmoplantar lesions associated with palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2009; 23:1227.</a></li><li><a class="nounderline abstract_t">Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003; 120:627.</a></li><li><a class="nounderline abstract_t">Song H, Yin W, Ma Q. Allergic palmoplantar pustulosis caused by cobalt in cast dental crowns: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111:e8.</a></li><li><a class="nounderline abstract_t">Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Expert Rev Clin Immunol 2020; 16:253.</a></li><li><a class="nounderline abstract_t">Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol 2019; 143:1021.</a></li><li><a class="nounderline abstract_t">Noe MH, Wan MT, Mostaghimi A, et al. Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. JAMA Dermatol 2022; 158:68.</a></li><li><a class="nounderline abstract_t">Murakami M, Ohtake T, Horibe Y, et al. Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 2010; 130:2010.</a></li><li><a class="nounderline abstract_t">Hagforsen E, Edvinsson M, Nordlind K, Michaëlsson G. Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 2002; 146:383.</a></li><li><a class="nounderline abstract_t">Hagforsen E, Hedstrand H, Nyberg F, Michaëlsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163:572.</a></li><li><a class="nounderline abstract_t">Kim DY, Kim JY, Kim TG, et al. A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx. J Eur Acad Dermatol Venereol 2013; 27:1559.</a></li><li><a class="nounderline abstract_t">Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20:845.</a></li><li><a class="nounderline abstract_t">Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis: A review. J Dermatol 2019; 46:931.</a></li><li><a class="nounderline abstract_t">Murakami M, Terui T. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. J Dermatol Sci 2020; 98:13.</a></li><li><a class="nounderline abstract_t">Murakami M, Kaneko T, Nakatsuji T, et al. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS One 2014; 9:e110677.</a></li><li><a class="nounderline abstract_t">Eriksson MO, Hagforsen E, Lundin IP, Michaëlsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998; 138:390.</a></li><li><a class="nounderline abstract_t">Hagforsen E, Nordlind K, Michaëlsson G. Skin nerve fibres and their contacts with mast cells in patients with palmoplantar pustulosis. Arch Dermatol Res 2000; 292:269.</a></li><li><a class="nounderline abstract_t">Sáez-Rodríguez M, Noda-Cabrera A, Alvarez-Tejera S, et al. The role of psychological factors in palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2002; 16:325.</a></li><li><a class="nounderline abstract_t">Takahara M. Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils. Adv Otorhinolaryngol 2011; 72:86.</a></li><li><a class="nounderline abstract_t">Kikuchi N, Yamamoto T. Dental infection as a triggering factor in palmoplantar pustulosis. Acta Derm Venereol 2013; 93:721.</a></li><li><a class="nounderline abstract_t">Akiyama T, Seishima M, Watanabe H, et al. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol 1995; 22:930.</a></li><li><a class="nounderline abstract_t">Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol 2017; 44:695.</a></li><li><a class="nounderline abstract_t">Koshiba S, Ichimiya S, Nagashima T, et al. Tonsillar crypt epithelium of palmoplantar pustulosis secretes interleukin-6 to support B-cell development via p63/p73 transcription factors. J Pathol 2008; 214:75.</a></li><li><a class="nounderline abstract_t">Ueda S, Takahara M, Tohtani T, et al. Up-regulation of ß1 integrin on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis Palmaris et Plantaris. J Clin Immunol 2010; 30:861.</a></li><li><a class="nounderline abstract_t">Sakiyama H, Kobayashi S, Dianzani U, et al. Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections. J Dermatol Sci 2008; 50:197.</a></li><li><a class="nounderline abstract_t">Yoshizaki T, Bandoh N, Ueda S, et al. Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol 2009; 157:71.</a></li><li><a class="nounderline abstract_t">Takahara M, Kishibe K, Nozawa H, Harabuchi Y. Increase of activated T-cells and up-regulation of Smad7 without elevation of TGF-beta expression in tonsils from patients with pustulosis palmaris et plantaris. Clin Immunol 2005; 115:192.</a></li><li><a class="nounderline abstract_t">Nozawa H, Kishibe K, Takahara M, Harabuchi Y. Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). Clin Immunol 2005; 116:42.</a></li><li><a class="nounderline abstract_t">Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164:942.</a></li><li><a class="nounderline abstract_t">Kouno M, Akiyama Y, Minabe M, et al. Dysbiosis of oral microbiota in palmoplantar pustulosis patients. J Dermatol Sci 2019; 93:67.</a></li><li><a class="nounderline abstract_t">Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67:e179.</a></li><li><a class="nounderline abstract_t">Shelling ML, Vitiello M, Lanuti EL, et al. A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect. J Clin Aesthet Dermatol 2012; 5:40.</a></li><li><a class="nounderline abstract_t">Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm Venereol 2010; 90:183.</a></li><li><a class="nounderline abstract_t">Seol JE, Park IH, Lee W, et al. Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis. Ann Dermatol 2016; 28:522.</a></li><li><a class="nounderline abstract_t">Yanagi T, Shimizu T, Abe R, Shimizu H. Zinc dental fillings and palmoplantar pustulosis. Lancet 2005; 366:1050.</a></li><li><a class="nounderline abstract_t">Nakamura K, Imakado S, Takizawa M, et al. Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules. J Am Acad Dermatol 2000; 42:1021.</a></li><li><a class="nounderline abstract_t">Kingo K, Mössner R, Kõks S, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol 2007; 156:646.</a></li><li><a class="nounderline abstract_t">Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol 2018; 178:740.</a></li><li><a class="nounderline abstract_t">Douroudis K, Kingo K, Traks T, et al. ATG16L1 gene polymorphisms are associated with palmoplantar pustulosis. Hum Immunol 2011; 72:613.</a></li><li><a class="nounderline abstract_t">Freitas E, Rodrigues MA, Torres T. Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations. Clin Cosmet Investig Dermatol 2020; 13:561.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Suárez-Fariñas M, Li X, et al. Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. PLoS One 2016; 11:e0155215.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28:1298.</a></li><li><a class="nounderline abstract_t">Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol 1971; 51:284.</a></li><li><a class="nounderline abstract_t">Enfors W, Molin L. Pustulosis palmaris et plantaris. A follow-up study of a ten-year material. Acta Derm Venereol 1971; 51:289.</a></li><li><a class="nounderline abstract_t">Barber HW. Acrodermatitis continua vel perstans (dermatitis repens) and psoriasis pustule. Br J Dermatol Syph 1930; 42:500.</a></li><li class="breakAll">Griffiths CE, Barker JN. Psoriasis. In: Rook's Textbook of Dermatology, 8th ed, Burns T, Breathnach S, Cox N, et al (Eds), Wiley-Blackwell, 2010. p.20.1.</li><li><a class="nounderline abstract_t">Trattner H, Blüml S, Steiner I, et al. Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol 2017; 31:1681.</a></li><li><a class="nounderline abstract_t">Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol 1996; 134:1079.</a></li><li><a class="nounderline abstract_t">Olazagasti JM, Ma JE, Wetter DA. Clinical Features, Etiologic Factors, Associated Disorders, and Treatment of Palmoplantar Pustulosis: The Mayo Clinic Experience, 1996-2013. Mayo Clin Proc 2017; 92:1351.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Hiraiwa T, Tobita R, et al. Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter study. Int J Dermatol 2020; 59:441.</a></li><li><a class="nounderline abstract_t">Kundu BK, Naik AK, Bhargava S, Srivastava D. Diagnosing the SAPHO syndrome: a report of three cases and review of literature. Clin Rheumatol 2013; 32:1237.</a></li><li><a class="nounderline abstract_t">Hagforsen E, Michaëlsson K, Lundgren E, et al. Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study. Acta Derm Venereol 2005; 85:225.</a></li><li><a class="nounderline abstract_t">Rosén K, Lindstedt G, Mobacken H, Nyström E. Thyroid function in patients with pustulosis palmoplantaris. J Am Acad Dermatol 1988; 19:1009.</a></li><li><a class="nounderline abstract_t">Giménez-García R, Sánchez-Ramón S, Cuellar-Olmedo LA. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol 2003; 17:276.</a></li><li><a class="nounderline abstract_t">Michaëlsson G, Kristjánsson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 2007; 156:659.</a></li><li><a class="nounderline abstract_t">Weisenseel P, Kuznetsov AV, Ruzicka T, Prinz JC. Palmoplantar pustulosis is not inevitably associated with antigliadin antibodies. Br J Dermatol 2007; 156:1399.</a></li><li><a class="nounderline abstract_t">Ishikawa M, Ohashi T, Eishi Y, Yamamoto T. Palmoplantar pustulosis in a patient with sarcoidosis. Eur J Dermatol 2020; 30:325.</a></li><li><a class="nounderline abstract_t">Marsland AM, Chalmers RJ, Hollis S, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; :CD001433.</a></li><li><a class="nounderline abstract_t">Yoon SY, Park HS, Lee JH, Cho S. Histological differentiation between palmoplantar pustulosis and pompholyx. J Eur Acad Dermatol Venereol 2013; 27:889.</a></li><li class="breakAll">Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier, 2010. p.123.</li><li><a class="nounderline abstract_t">Proença NG. Acropustulosis repens. Int J Dermatol 2006; 45:389.</a></li><li><a class="nounderline abstract_t">Gurgen J, Dorton D. Unusual case of pemphigus vulgaris mimicking localized pustular psoriasis of the hands and feet. Cutis 2010; 86:138.</a></li></ol></div><div id="topicVersionRevision">Topic 89272 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301847" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19467374" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20687846" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pustulosis palmoplantaris is a disease distinct from psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269621" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Palmoplantar pustulosis should not be considered as a variant of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223864" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A classification of psoriasis vulgaris according to phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25588781" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813766" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Palmoplantar pustulosis--a retrospective review of comorbid conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26081174" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The spontaneous regression of palmoplantar pustulosis following removal of dental amalgams: A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673108" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dramatic exacerbation of palmoplantar pustulosis following strongly positive nickel patch testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989471" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28585342" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : European consensus statement on phenotypes of pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453807" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extra-palmoplantar lesions associated with palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12648227" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21439867" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergic palmoplantar pustulosis caused by cobalt in cast dental crowns: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073337" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036598" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and genetic differences between pustular psoriasis subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34878495" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393482" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952537" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20426778" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23802874" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of inflammatory mediator expression between palmoplantar pustulosis and pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21732985" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31556151" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenic role of palatine tonsils in palmoplantar pustulosis: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32201085" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25330301" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580788" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Palmoplantar pustulosis: a clinical and immunohistological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10929766" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Skin nerve fibres and their contacts with mast cells in patients with palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12224686" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The role of psychological factors in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865698" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical outcome of tonsillectomy for palmoplantar pustulosis and etiological relationship between palmoplantar pustulosis and tonsils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462950" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dental infection as a triggering factor in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648000" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28150339" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992659" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tonsillar crypt epithelium of palmoplantar pustulosis secretes interleukin-6 to support B-cell development via p63/p73 transcription factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20714794" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Up-regulation ofß1 integrin on tonsillar T cells and its induction by in vitro stimulation withα-streptococci in patients with pustulosis Palmaris et Plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308514" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659772" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15885643" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Increase of activated T-cells and up-regulation of Smad7 without elevation of TGF-beta expression in tonsils from patients with pustulosis palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925831" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21275942" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Management of palmoplantar pustulosis: do we need to change?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30655103" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dysbiosis of oral microbiota in palmoplantar pustulosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752492" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-αinhibitors: the Mayo Clinic experience, 1998 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22916313" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20169304" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Paradoxical reactions to targeted biological treatments: A way to treat and trigger?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489447" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16168788" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Zinc dental fillings and palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10827407" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263806" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28887889" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The genetic basis for most patients with pustular skin disease remains elusive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21513755" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : ATG16L1 gene polymorphisms are associated with palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32884319" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152848" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24112799" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4105777" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4105778" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pustulosis palmaris et plantaris. A follow-up study of a ten-year material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acrodermatitis continua vel perstans (dermatitis repens) and psoriasis pustule</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Acrodermatitis continua vel perstans (dermatitis repens) and psoriasis pustule</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28252813" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8763428" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The spectrum of nail involvement in palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28764899" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical Features, Etiologic Factors, Associated Disorders, and Treatment of Palmoplantar Pustulosis: The Mayo Clinic Experience, 1996-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985054" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23604547" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnosing the SAPHO syndrome: a report of three cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040407" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3204175" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thyroid function in patients with pustulosis palmoplantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702064" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263812" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535244" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Palmoplantar pustulosis is not inevitably associated with antigliadin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32666935" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Palmoplantar pustulosis in a patient with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437433" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Interventions for chronic palmoplantar pustulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691103" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Histological differentiation between palmoplantar pustulosis and pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691103" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Histological differentiation between palmoplantar pustulosis and pompholyx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650164" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acropustulosis repens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21049731" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Unusual case of pemphigus vulgaris mimicking localized pustular psoriasis of the hands and feet.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
